Sequence Information

    • DRAMP ID

    • DRAMP18159

    • Name

    • Oritavancin

    • Sequence

    • Not available

    • Description

    • Oritavancin is a glycopeptide antibiotic used to treat acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria. It was developed by The Medicines Company (acquired by Novartis).

    • Activity

    • Antibacterial

    • Target Organism

      • No MICs found on DRAMP database

    • Reference

      • Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin.(PMID: 25403671)

Clinical Information

    • Medical use

    • Treatment of adult patients with acute bacterial skin and skin structure (including subcutaneous) infection.

    • Company

    • The Medicines Company

    • Stage of Development

    • In market

    • Comments

    • Oritavancin works against susceptible gram-positive organisms via three separate mechanisms. Firstly, it binds to the stem peptide of peptidoglycan precursors, inhibiting transglycosylation (polymerization). This process normally occurs during cell wall synthesis. Secondly, oritavancin inhibits crosslinking during bacterial cell wall biosynthesis via binding to cell wall pentaglycyl peptide bridging segments. Finally, this drug also acts by disrupting the bacterial cell membrane, interfering with its integrity, which eventually leads to cell death by various mechanisms.